 |
Haleon plc: Director Declaration
28 September 2023: In accordance with paragraph 9.6.14R of the Listing Rules of the UK Financial Conduct Authority, Haleon plc (the "Company") (LSE/NYSE: HLN) notes that Deirdre Mahlan, an Independent Non-Executive Director and Chair of the Audit & Risk Committee of the Company has been appointed Interim President, Chief Executive Officer and Chairperson of the Board of The Duckhorn Portfolio, Inc. (NYSE: NAPA) with immediate effect from 27 September 2023.
There is no further information to be disclosed in respect of paragraph 9.6.14.
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
